An interventional study of Repetitive transcranial magnetic stimulation (rTMS) - active and Repetitive transcranial magnetic stimulation (rTMS) - inactive in Cancer and Chronic Neuropathic Pain, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
High-frequency repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex (M1) has shown its efficacy to alleviate pain in patients suffering from refractory neuropathic pain. rTMS is now considered as 3rd-line therapy (by the French Society for the Study and Treatment of Pain) for patient's refractory to drug therapy.
However, its efficacy in chronic neuropathic pain related to cancer has not yet been specifically studied, and it therefore remains relatively inaccessible for these patients. This project is a cross-over, double-blinded, and placebo-control study, including 5 sessions of either M1 or "sham" rTMS, a wash-out period (8 weeks), followed by 5 sessions of the other stimulation option (I.e., two arms: M1-sham or sham-M1; order randomized between patients). Treatment efficacy will be assessed in comparison to the placebo condition. Primary outcome is the percentage of pain relief between active and sham rTMS. Other variables to describe quality of life, sensory, neuropathic, and mood states as well as resting-state fMRI will be collected before and after treatment.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's planned enrollment of 60 is close to the median of 60 across 7,716 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 598 studies on the registry; 128 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 stimulation sessions on M1 - washout 8 weeks - 5 sham stimulation sessions (placebo-control, same site, inactive stimulation)
Device: Repetitive transcranial magnetic stimulation (rTMS) - active · Device: Repetitive transcranial magnetic stimulation (rTMS) - inactive
5 sham stimulation sessions (placebo-control, same site, inactive stimulation) - washout 8 weeks - 5 stimulation sessions on M1
Device: Repetitive transcranial magnetic stimulation (rTMS) - active · Device: Repetitive transcranial magnetic stimulation (rTMS) - inactive
rTMS session active on the primary motor cortex
rTMS session inactive on the primary motor cortex
PAIN RELIEF
PAIN from 0% : no pain relief at all to 100%: completely relief.
Time frame: Week 7 after the start of RTMs stimulation
Pain Intensity with Visual analog scale (VAS)
0 no pain to 10 extremely pain
Time frame: day 7 post RTMs stimulation
score of Neuropathic Pain Symptom Inventory - NPSI
\[0= zero neuropatthic pain to 100= maximum neuropathic pain\]
Time frame: day 7 post RTMs stimulation
Brief Pain Inventory - BPI
1 - 4 = Mild Pain. 5 =Worst Pain Score 6 = Moderate Pain. 7=Worst Pain Score 10 = Severe Pain.
Time frame: day 7 post RTMs stimulation
Pain relief
scale ranging from 0% = no relief to 100% = fully relieved
Time frame: day 7 post RTMs stimulation
Visual Analogic Scale VAS on emotional dimension of pain
Visual Analogic Scale VAS (0 = not unpleasant) to 10 = extremely unpleasant)
Time frame: day 7 post RTMs stimulation
Visual Analogic Scale (VAS) on attentional dimension of pain
0 = does not attract at all to 10 = completely attracts
Time frame: day 7 post RTMs stimulation
consumption of rescue analgesics
Time frame: Week 7 after the start of RTMs stimlulation
Effect of rTMS on quality of life
Quality of life score (EQ-5D) from 0 to 100. 100 corresponds to the best health.
Time frame: Week 7 after the start of RTMs stimlulation
HADS: Hospital Anxiety and Depression Scale
from 0 to 14: no anxiety disorders; from 15 to 42: existence of anxiety disorders.
Time frame: Week 7 after the start of RTMs stimlulation
Tolerance
Tolerance will be defined as the absence of adverse effects throughout the duration of the protocol, as reported in systematic questionnaires."
Time frame: week 7 after the start of RTMs stimulation
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Nov 2028, 41 months after the start.
Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 41 months is above that.
Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Saint Etienne →